CoChat

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Open access
Björk, Jonas, Bonander, Carl, Moghaddassi, Mahnaz, Rasmussen, Magnus, Malmqvist, Ulf, Inghammar, Malin, Kahn, Fredrik · 2022 · Eurosurveillance
Cited by 47

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2807/1560-7917.es.2022.27.18.2200322

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 9

  1. Lyngse, 2022.01.28.22270044, Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households., medRxiv
  2. Kirsebom, 2022.03.22.22272691, COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England., medRxiv
  3. Altarawneh, 2022.03.22.22272745, Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar., medRxiv
  4. Björk, 2022, High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden., Infect Dis (Lond), 54, 128, 10.1080/23744235.2021.1982144 · DOI · Paper page
  5. Kahn, 2022, Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022., Euro Surveill, 27, 10.2807/1560-7917.ES.2022.27.9.2200121 · DOI
  6. Dean, 2019, Re: "Measurement of vaccine direct effects under the test-negative design"., Am J Epidemiol, 188, 806, 10.1093/aje/kwz019 · doi:10.1093/aje/kwz019
  7. Inghammar, 2021.08.12.21261981, COVID-19 vaccine uptake among older people in relation to sociodemographic factors –cohort results from southern Sweden., medRxiv
  8. Eales, 2022.03.29.22273042, The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England., medRxiv
  9. Nordström, 2022, Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden., Lancet Infect Dis, 10.1016/S1473-3099(22)00143-8 · DOI · Paper page

Cited by

See all 47

Metadata

Authors
Björk, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Inghammar, M., & Kahn, F.
Venue
Eurosurveillance
Published
2022-05-05
Volume
27
Issue
18
ISSN
  • 1025-496X (ISSN-L)
  • 1560-7917
OpenAlex
W4229022258
Cited by
47
References
2
FWCI
5.22
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. https://app.cochat.ai/papers/10.2807/1560-7917.es.2022.27.18.2200322
The paper
Björk, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Inghammar, M., & Kahn, F. (2022). COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. Eurosurveillance. https://doi.org/10.2807/1560-7917.es.2022.27.18.2200322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.